Antifungal Potential of Flavonoids Against Drug-Resistant Fungal Pathogens
Journal of Pharma Insights and Research · 2026
DOI: 10.69613/034f4q93 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharma Insights and Research, 2026. Verfasst von Pooja Sahu und 3 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Invasive fungal infections represent a critical global health challenge characterized by expanding at-risk patient cohorts, unacceptable mortality rates, and progressive resistance across conventional antifungal classes. The therapeutic arsenal remains constrained by end-organ toxicities, narrow empirical spectra, unfavorable pharmacokinetics, and a sparse developmental pipeline. Plant secondary metabolites, particularly polyphenolic flavonoids, provide structurally versatile chemical scaffolds with broad-spectrum antimycotic potential against high-priority pathogens including Candida, Aspergillus, Cryptococcus, and emergent filamentous moulds. Flavonoids exert multimodal fungicidal and fungistatic pressure through simultaneous biological targets: disrupting fungal plasma membrane integrity via sterol destabilization, compromising cell wall architecture through β-glucan and chitin dysregulation, uncoupling mitochondrial electron transport chains, inducing endogenous reactive oxygen species generation, suppressing nucleic acid and protein biosyntheses, impeding cell division cycles, inhibiting dimorphic yeast-to-hyphal phenotypic shifts, and dampening ATP-binding cassette or major facilitator superfamily efflux pumps. When co-administered with conventional polyenes, azoles, or echinocandins, flavonoids systematically reverse multidrug-resistant phenotypes, showing marked in vitro and in vivo chemosensitization and synergy. Nevertheless, translational hurdles such as poor aqueous solubility, rapid systemic phase II clearance, variable membrane permeation, and sub-micromolar stability impede direct clinical deployment. Overcoming these pharmacokinetic constraints demands rationally engineered nano-formulations, polymeric encapsulation, and semisynthetic structural optimization. Exploiting bioactive flavonoids as standalone scaffolds or synergistic clinical adjuvants provides a viable therapeutic paradigm to alleviate fungal morbidity, restore conventional drug susceptibility, and forestall antimicrobial resistance development worldwide.
Zitieren
APA
Sahu, P., Kaur, C. D., Sahu, S., & Dewangan, R. (2026). Antifungal Potential of Flavonoids Against Drug-Resistant Fungal Pathogens. Journal of Pharma Insights and Research. https://doi.org/10.69613/034f4q93
Vancouver
Sahu P, Kaur CD, Sahu S, Dewangan R. Antifungal Potential of Flavonoids Against Drug-Resistant Fungal Pathogens. Journal of Pharma Insights and Research. 2026. doi:10.69613/034f4q93
BibTeX
@article{Sahu2026,
author = {Sahu, Pooja and Kaur, Chanchal Deep and Sahu, Shobha and Dewangan, Ritu},
title = {Antifungal Potential of Flavonoids Against Drug-Resistant Fungal Pathogens},
journal = {Journal of Pharma Insights and Research},
year = {2026},
doi = {10.69613/034f4q93}
}
EUVIMED